Active ingredient
- molnupiravir
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 53095/0089.
Lagevrio 200 mg hard capsules
Package leaflet: Information for the patient
Lagevrio® 200 mg hard capsules
molnupiravir
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Lagevrio is and what it is used for
2. What you need to know before you take Lagevrio
3. How to take Lagevrio
4. Possible side effects
5. How to store Lagevrio
6. Contents of the pack and other information
1. What Lagevrio is and what it is used for
Lagevrio contains the active substance molnupiravir. Lagevrio is an antiviral medicine used to treat mild to moderate COVID-19 (caused by SARS-CoV-2) in adults who are at risk for developing severe illness.
Lagevrio may help people with COVID-19 stay out of the hospital and feel better.
2. What you need to know before you take Lagevrio
Do not take Lagevrio
Warnings and precautions
Talk to your doctor or pharmacist before taking molnupiravir.
Children and adolescents
Do not give this medicine to children and adolescents aged less than 18 years. The use of Lagevrio in persons aged less than 18 years has not yet been studied.
Other medicines and Lagevrio
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Pregnancy and breast-feeding
Animal studies with molnupiravir have shown harmful effects to the unborn animal. Lagevrio is not recommended in pregnancy. Lagevrio has not been studied in pregnancy and it is not known if Lagevrio will harm your baby while you are pregnant.
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice. If you can become pregnant, you should use effective birth control while you are taking Lagevrio and for 4 days after the last dose of Lagevrio.
If you are breast-feeding or are planning to breastfeed, tell your doctor before taking this medicine. Breast-feeding is not recommended during treatment and for 4 days after the last dose of Lagevrio. This is because it is not known if Lagevrio gets into breast milk and will be passed to the baby.
Driving and using machines
No studies on the effects on the ability to drive and use machines have been performed.
Lagevrio contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose of 4 capsules, that is to say essentially ‘sodium-free’.
3. How to take Lagevrio
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
You should start Lagevrio within 5 days of the onset of COVID-19 symptoms.
How much to take
The recommended dose of Lagevrio is four 200 mg capsules, every 12 hours for 5 days.
How to take
If you take more Lagevrio than you should
If you take more Lagevrio than you should, contact your doctor straight away.
If you forget to take Lagevrio
Do not stop taking Lagevrio
Do not stop taking Lagevrio without talking to your doctor first. This will give the medicine the best chance to keep you from becoming severely ill from COVID-19.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Coronavirus Yellow Card Reporting site at https://coronavirus-yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
5. How to store Lagevrio
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special temperature storage conditions. Store in the original package.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
6. Contents of the pack and other information
What Lagevrio contains
The active substance is molnupiravir. Each hard capsule contains 200 mg of molnupiravir.
The other ingredients are:
Capsule content: Croscarmellose sodium (E468), hydroxypropyl cellulose (E463), magnesium stearate (E470b), microcrystalline cellulose (E460).
Capsule shell: Hypromellose (E464), titanium dioxide (E171), red iron oxide (E172).
Printing ink: Butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol (E1520), purified water, shellac, strong ammonia solution, and titanium dioxide (E171).
What Lagevrio looks like and contents of the pack
Lagevrio 200 mg hard capsule is a Swedish Orange opaque, size 0 (approximately 21.7 mm x 7.6 mm) hard capsule, printed with MSD corporate logo on the cap and “82” on the body in white ink.
Lagevrio 200 mg hard capsules are supplied in high-density polyethylene (HDPE) bottles with a polypropylene cap containing 40 capsules.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder:
Manufacturer:
For any information about this medicine, please contact:
This leaflet was last revised in November 2021
This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.
Other sources of information
www.molnupiravir.com/uk
© Merck Sharp & Dohme (UK) Limited, 2021. All rights reserved.
PIL.LAG.21.GB.7919.NewMA.NoRCN
120 Moorgate, London, EC2M 6UR, UK
+44 (0)208 154 8000
+44 (0)2081548001